NASDAQ:GNLX

Genelux Q3 2026 Earnings Results & Report

Genelux logo
$2.00 +0.08 (+4.17%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$2.03 +0.03 (+1.70%)
As of 11/17/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genelux missed analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.23 versus the -$0.1983 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
7:00 AM ET

Genelux EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.1983
Beat/Miss
Missed by -$0.0317
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Genelux Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Genelux's Q4 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules

Genelux Q3 2026 Earnings FAQ

Genelux (NASDAQ:GNLX) reported earnings of -$0.23 per share for Q3 2026, missing the consensus estimate of -$0.1983. The report was announced on Monday, November 16, 2026.

Genelux's next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Genelux on the company's earnings history page.

Genelux Earnings Headlines

A $247 tool for $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
See More Genelux Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genelux? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genelux and other key companies, straight to your email.

About Genelux

Genelux (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors.

The company’s lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform.

Headquartered in Westlake Village, California, Genelux conducts research and clinical development of its therapies. Its work is focused on evaluating whether oncolytic viruses can offer new treatment options for people with cancer.

View Genelux Profile